Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

Abstract Introduction Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phase IIb trials investigated the long-term safety and effectiveness of peficitinib. M...

Full description

Bibliographic Details
Main Authors: Mark C. Genovese, Maria W. Greenwald, Sergio R. Gutierrez-Ureña, Mario H. Cardiel, Jeffrey E. Poiley, Anna Zubrzycka-Sienkiewicz, Christine E. Codding, Annie Wang, Weizhong He, Rebecca Amos, Raul Vinueza, Xuegong Wang, Jay P. Garg, Alan J. Kivitz
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-08-01
Series:Rheumatology and Therapy
Subjects:
Janus kinase (JAK) inhibitor
Long-term extension
Peficitinib
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1007/s40744-019-00167-6

Internet

http://link.springer.com/article/10.1007/s40744-019-00167-6

Similar Items